Novo Nordisk A/S Class B

Novo Nordisk A/S Sponsored Canadian Depository Receipt Hedged Reg S's next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Novo Nordisk A/S Sponsored Canadian Depository Receipt Hedged Reg S maintains a current ratio of 0.87, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 63.33, indicating elevated leverage, while an interest coverage ratio of 273.09 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Novo Nordisk A/S Sponsored Canadian Depository Receipt Hedged Reg S posted a return on equity (ROE) of 59.82, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 33.40 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 21.62, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 37.19, useful for judging operating efficiency across full business cycles. The company generates approximately 1.01M in revenue per employee across its workforce of 70,671.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.31 indicates how many times Novo Nordisk A/S Sponsored Canadian Depository Receipt Hedged Reg S sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Novo Nordisk A/S Sponsored Canadian Depository Receipt Hedged Reg S recorded 7.01B in income tax expense. That works out to an effective tax rate of 21.72, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 32.27B, leaving 25.26B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Novo Nordisk A/S Sponsored Canadian Depository Receipt Hedged Reg S's stock has declined approximately 24.29% over the past 52 weeks. The 50-day moving average sits at 4.48, while the 200-day moving average is 4.70.

These figures cover the twelve months ended June 30, 2026. EBITDA reached 35.13B, while operating income came in at 30.83B.

As of June 30, 2026, Novo Nordisk A/S Sponsored Canadian Depository Receipt Hedged Reg S holds 9.76B in cash and equivalents against 30.40B in total debt, resulting in a net debt position of 20.75B. Total book value stands at 48.01B, with working capital of -6.59B providing operational flexibility.

Novo Nordisk A/S Sponsored Canadian Depository Receipt Hedged Reg S produced 28.61B in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Novo Nordisk A/S Sponsored Canadian Depository Receipt Hedged Reg S posted a gross margin of 80.65, reflecting its pricing power and cost economics. The operating margin of 43.13 and net profit margin of 35.35 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. The dividend payout ratio of 44.64 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.